Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Marie Grouin

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Statistics in Medicine|February 23, 2011
Sixth International French Society of Statistics meeting on statistical methods in biopharmacy: recent advances and trends in statistics as applied to clinical trialsJean-Marie Grouin, Michael Campbell
Statistics in Medicine|February 26, 2004
Adjustment for baseline covariates: an introductory noteJean-Marie Grouin, Simon Day, John Lewis
Journal of Biopharmaceutical Statistics|August 5, 2005
Subgroup analyses in randomized clinical trials: statistical and regulatory issuesJean-Marie Grouin, Maylis Coste, John Lewis
Statistics in Medicine|June 15, 2007
Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerationsJean-Marie Grouin, Maylis Coste, Pierre Bunouf, et al.
Diabetes, Obesity & Metabolism|December 4, 2020
Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trialJulie Dubourg, Kohjiro Ueki, Jean-Marie Grouin, et al.
Neurology and Therapy|May 28, 2024
Relative Bioavailability Study of Midazolam Intramuscularly Administered with the Needle-Free Auto-Injector ZENEO<sup>®</sup> in Healthy AdultsOlivier Lacombe, Yannick Pletan, Jean-Marie Grouin, et al.
Diabetes, Obesity & Metabolism|December 6, 2021
Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trialJulie Dubourg, Pascale Fouqueray, Damien Quinslot, et al.
Diabetes Care|February 12, 2021
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 TrialJulie Dubourg, Pascale Fouqueray, Carole Thang, et al.
Human Psychopharmacology|January 13, 2018
Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorderSidney H Kennedy, Jean-Marie Grouin, Stéphanie Cadour, et al.
Diabetes, Obesity & Metabolism|January 5, 2022
Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension periodCaroline Reilhac, Julie Dubourg, Carole Thang, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Statistics in Medicine|February 23, 2011
Sixth International French Society of Statistics meeting on statistical methods in biopharmacy: recent advances and trends in statistics as applied to clinical trialsJean-Marie Grouin, Michael Campbell
Statistics in Medicine|February 26, 2004
Adjustment for baseline covariates: an introductory noteJean-Marie Grouin, Simon Day, John Lewis
Journal of Biopharmaceutical Statistics|August 5, 2005
Subgroup analyses in randomized clinical trials: statistical and regulatory issuesJean-Marie Grouin, Maylis Coste, John Lewis
Statistics in Medicine|June 15, 2007
Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerationsJean-Marie Grouin, Maylis Coste, Pierre Bunouf, et al.
Diabetes, Obesity & Metabolism|December 4, 2020
Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trialJulie Dubourg, Kohjiro Ueki, Jean-Marie Grouin, et al.
Neurology and Therapy|May 28, 2024
Relative Bioavailability Study of Midazolam Intramuscularly Administered with the Needle-Free Auto-Injector ZENEO<sup>®</sup> in Healthy AdultsOlivier Lacombe, Yannick Pletan, Jean-Marie Grouin, et al.
Diabetes, Obesity & Metabolism|December 6, 2021
Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trialJulie Dubourg, Pascale Fouqueray, Damien Quinslot, et al.
Diabetes Care|February 12, 2021
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 TrialJulie Dubourg, Pascale Fouqueray, Carole Thang, et al.
Human Psychopharmacology|January 13, 2018
Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorderSidney H Kennedy, Jean-Marie Grouin, Stéphanie Cadour, et al.
Diabetes, Obesity & Metabolism|January 5, 2022
Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension periodCaroline Reilhac, Julie Dubourg, Carole Thang, et al.
Pageof 4